News Search Results
Aug 27, 2024, 10:30 ET Clearance of Circulating Tumor HPV-DNA, Monitored Using HPV-SEQ, Predicts Improved Survival: A JAMA Oncology Publication
Inostics Inc., a subsidiary of Japan's Sysmex Corporation and Baltimore-based biotechnology firm and CLIA-certified lab, in collaboration with the University of Chicago Medicine announces the publication of results
More news about: Sysmex Inostics
Aug 27, 2024, 10:30 ET Immunohistochemistry (IHC) Market worth $5.2 billion by 2029 driven by Emerging Tech Innovations | MarketsandMarkets™
heightened awareness of healthcare diagnostics, rising approval rates for therapeutic antibodies, and increased R&D spending by pharmaceutical and biotechnology companies. Application Segment: Research Applications Contribute Significantly The IHC market is segmented by application into
More news about: MarketsandMarkets
Aug 27, 2024, 10:28 ET GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients
patent applications and great numbers of know-how secrets. Driven by the corporate mission of "Make People and Nature Healthier Through Biotechnology", GenScript Biotech strives to become the most trustworthy biotech company in the world. For more information, please visit GenScript Biotech's
More news about: GenScript Biotech Corporation
Aug 27, 2024, 08:30 ET Texas Research Quarter Receives City of Plano Approval for Development Agreement Supporting Life Sciences Real Estate Project
confident that the Texas Research Quarter will emerge as a pivotal center, further solidifying the metroplex's reputation as the 'Third Coast' for biotechnology research and manufacturing," said Doug McDonald, Director Economic Development with the City
More news about: Texas Research Quarter
Aug 27, 2024, 08:15 ET Psilera receives positive preclinical in vivo data for frontotemporal dementia (FTD) candidate, PSIL-006
Fla., Aug. 27, 2024 /PRNewswire/ -- Psilera, Inc. (Psilera), a leading biotechnology company developing therapies for rare neurological disorders, has received initial toxicity readouts from maximum tolerated dose (MTD) in vivo
More news about: Psilera, Inc.
Aug 27, 2024, 08:00 ET ProJenX Announces Formation of Clinical Advisory Board
YORK, Aug. 27, 2024 /PRNewswire/ -- ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS)
More news about: ProJenX
Aug 27, 2024, 07:05 ET REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
6:15 p.m. WEST (Western European Summer Time) About REGENXBIO Inc.REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development
More news about: REGENXBIO Inc.
Aug 27, 2024, 07:00 ET Remix Therapeutics to Participate in Upcoming Investor Conferences
Mass., Aug. 27, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced that management
More news about: Remix Therapeutics
Aug 27, 2024, 06:45 ET Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 27, 2024, 05:11 ET JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration
More news about: JW Therapeutics
Aug 27, 2024, 05:00 ET JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration
More news about: JW Therapeutics
Aug 27, 2024, 03:00 ET Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT
BASEL, Switzerland, Aug. 27, 2024 /PRNewswire/ -- Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announces positive results from its randomized,
More news about: Vaderis Therapeutics AG
Aug 27, 2024, 03:00 ET Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT
Aug. 27, 2024 /PRNewswire/ -- Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announces positive results from its randomized,
More news about: Vaderis Therapeutics AG
Aug 26, 2024, 19:36 ET Angel Yeast expandiert in Forschung, Entwicklung und Produktion von Probiotika und treibt biotechnologische Transformation voran
bauen wir auch eine lokale Talentpipeline mit Fachleuten aus den Bereichen Management, Finanzen und Ausrüstung auf. Die Xizang Angel Zhufeng Biotechnology Co. Ltd. besitzt alle unabhängigen Eigentumsrechte, von den wichtigsten Stämmen bis zu den Produktionsprozessen. Die Produktion ist vollständig
More news about: Angel Yeast
Aug 26, 2024, 19:18 ET Angel Yeast se expande hacia I+D y producción de probióticos y avanza en la transformación biotecnológica
Xizang, también estamos creando una cantera de talento local de profesionales en gestión, finanzas y equipamiento". Xizang Angel Zhufeng Biotechnology Co., Ltd. posee derechos de propiedad completamente independientes desde las cepas clave hasta los procesos de producción, y el taller de la fábrica
More news about: Angel Yeast
Aug 26, 2024, 16:25 ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
[Click here for information about joining the class action] Ardelyx is a biotechnology company focused on developing and commercializing therapies for, among other things, patients with chronic kidney disease ("CKD"). According to
More news about: Pomerantz LLP
Aug 26, 2024, 16:20 ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRNA
[Click here for information about joining the class action] Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases,
More news about: Pomerantz LLP
Aug 26, 2024, 10:30 ET Ultraviolet Visible Spectroscopy Market worth $1.7 billion by 2029 driven by Emerging Tech Innovations | MarketsandMarkets™
the life sciences industry, offering analytical instruments, equipment, consumables, and software to over 400,000 clients across pharmaceutical, biotechnology, academic, and government sectors. Operating in four segments—Laboratory Products & Services, Life Sciences Solutions, Analytical Instruments,
More news about: MarketsandMarkets
Aug 26, 2024, 10:24 ET BPC secures additional orders from a multinational oil and gas company for biogas production
instruments enabling more efficient, reliable, and higher quality research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision but also a significant reduction in time consumption and labor requirements for performing
More news about: BPC Instruments AB
Aug 26, 2024, 10:20 ET Angel Yeast Expands into Probiotics R&D and Production, Advances Biotech Transformation
project in Xizang we're also building a local talent pipeline of management, finance, and equipment professionals." The Xizang Angel Zhufeng Biotechnology Co., Ltd. owns full independent property rights from the key strains to production processes, and the factory workshop is fully digitalized and
More news about: Angel Yeast
Aug 26, 2024, 09:02 ET DELFI Diagnostics Appoints Thomas Russo as Chief Financial Officer
Inc., and senior finance and commercial operations roles at Gilead Sciences, Inc. Previously, he served as Equity Research Senior Analyst covering biotechnology for Robert W. Baird & Co. Inc., where he earned WSJ Best on the Street recognition. Earlier in his career, Mr. Russo worked in roles of increasing
More news about: DELFI Diagnostics
Aug 26, 2024, 08:30 ET Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 26th Annual Global
More news about: Anixa Biosciences, Inc.
Aug 26, 2024, 08:30 ET Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
significant in depression About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong
More news about: Actinogen Medical Limited
Aug 26, 2024, 07:30 ET Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
Aug. 26, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Aug 26, 2024, 07:00 ET Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development
low dose of JCXh-1108 achieved complete protection against RSV virus challenge. About Immorna Immorna is a rapidly expanding biotechnology company, focusing on the development of RNA-based therapeutics and vaccines. Immorna is utilizing multiple RNA platforms, including conventional,
More news about: Immorna Biotherapeutics, Inc.